Venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Item
http://www.wikidata.org/entity/Q42348732
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.Combination therapy with the type II anti-CD20 antibody obinutuzumab.Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma.Bendamustine plus rituximab in chronic lymphocytic leukemia: is there life in the old dog yet?Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?
P2860

Venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Item
http://www.wikidata.org/entity/Q42348732
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
@en
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
@nl
type
label
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
@en
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
@nl
prefLabel
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
@en
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
@en
P2093
P2860
P304
P31
P356
10.1182/BLOOD-2017-01-761973
P407
P433
P478
P50
P577
P698
P921
P932